8-KLeadership Changes

Merck & Co., Inc. 8-K Report, Executive Changes (Dec 10, 2018)

Filed December 10, 2018For Securities:MRK

Summary

Merck & Co., Inc. (MRK) announced the departure of Mr. Adam Schechter, Executive Vice President and President of Global Human Health, effective December 31, 2018. Mr. Schechter will transition to a special advisor role before leaving the company. This change is part of a broader restructuring and elimination of his position within the organization. In connection with his departure, Mr. Schechter is eligible for benefits under Merck's U.S. Separation Benefits Plan, which includes 78 weeks of separation pay and certain health and welfare benefits, contingent on signing a release and adhering to restrictive covenants. Additionally, Merck will pay Mr. Schechter $1,000,000 for a one-year non-competition agreement, underscoring the strategic importance of retaining competitive advantage.

Key Highlights

  • 1Adam Schechter, EVP and President of Global Human Health, is departing effective December 31, 2018.
  • 2Mr. Schechter will serve as a special advisor before his departure.
  • 3His position is being eliminated as part of a company restructuring.
  • 4Mr. Schechter will receive 78 weeks of separation pay and health benefits.
  • 5A $1,000,000 payment will be made for a one-year non-competition agreement.
  • 6Benefits are contingent on signing a release of claims and adhering to restrictive covenants.

Frequently Asked Questions

Mr. Adam Schechter is stepping down from his role as Executive Vice President and President of Global Human Health due to a restructuring and elimination of his position within the company.

Mr. Schechter is eligible for 78 weeks of separation pay and certain health and welfare benefits under Merck's U.S. Separation Benefits Plan. Additionally, he will receive $1,000,000 for agreeing to a one-year non-competition agreement.

Yes, the benefits are contingent upon Mr. Schechter executing a general release of claims against Merck and continuing to comply with certain restrictive covenants, including the non-competition agreement.

The primary disclosed financial impact is the $1,000,000 payment for the non-competition agreement and the provision of separation pay and benefits. The specific value of these benefits is not fully detailed but will be an expense for the company.